Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/740260/000074026021000101/vtr-20210331.htm
May 2022
May 2022
March 2022
February 2022
January 2022
January 2022
November 2021
November 2021
September 2021
August 2021
CHICAGO--(BUSINESS WIRE)--May 7, 2021--Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) today reported results for the first quarter ended March 31, 2021.
“Our strong, diverse and high-quality portfolio delivered better than expected financial results in the first quarter, driven by outperformance in our Senior Housing Operating Portfolio (“SHOP”) and the reliable performance of our Office and Triple-Net (“NNN”) businesses,” said Debra A. Cafaro, Ventas Chairman and CEO.
“Most importantly, led by a 280 basis point increase in our U.S. communities, occupancy in SHOP improved by 190 basis points from pandemic lows in mid-March through the end of April. We have experienced dramatic benefits in resident health and safety from the broad and effective roll out of vaccines earlier in the first quarter. With leads continuing to gain traction, and all our communities open to new move-ins, March and April were the first two consecutive months since the onset of COVID-19 when move-ins exceeded both pre-pandemic levels and move-outs. This improvement, while still in its early stages, demonstrates resilient demographic demand for senior housing and the essential care and socialization available to residents in our communities. These factors provide the basis for the powerful upside that lies ahead in senior housing and for Ventas as an industry leader.
“We are optimistic about our ongoing initiatives to recycle capital to further enhance the quality of our portfolio, fund new investment opportunities and maintain financial strength and flexibility. The emerging momentum in SHOP, combined with our high-quality portfolio, leading operators and partners and experienced leadership, position Ventas to win the recovery,” Cafaro concluded.
First Quarter 2021 Results
(per share)
For the first quarter 2021, reported per share results were: | ||||
|
Quarter Ended March 31 |
|||
|
2021 |
2020 |
$ Change |
% Change |
Net Income (Loss) Attributable to Common Stockholders |
($0.15) |
$1.26 |
($1.41) |
(112%) |
Nareit FFO Attributable to Common Stockholders (“Nareit FFO”)* |
$0.67 |
$1.31 |
($0.64) |
(49%) |
Normalized FFO Attributable to Common Stockholders (“Normalized FFO”)* |
$0.72 |
$0.97 |
($0.25) |
(26%) |
* |
This is a non-GAAP financial measure. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release and our first quarter 2021 supplemental for additional information and a reconciliation to the most directly comparable GAAP measure. |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/740260/000074026021000101/vtr-20210331.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ventas Inc.
Ventas Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
Merger-Related Expenses and Deal Costs The $3.6 million decrease in merger-related expenses and deal costs is primarily attributable to severance related charges and captive insurance organizational costs incurred in 2020.
While continuing decreased revenue and net operating income as a result of the COVID-19 pandemic could lead to downgrades of our long-term credit rating and therefore adversely impact our cost of borrowing, we currently believe we will continue to have access to one or more debt markets during the duration of the pandemic and could seek to enter into secured debt financings or issue debt and equity securities to satisfy our liquidity needs, although no assurances can be made in this regard.
Other Items In March 2021, the Ventas Life Science and Healthcare Real Estate Fund, L.P. (the "Ventas Fund") acquired two Class-A life science properties in the Baltimore-DC life science cluster for $272 million, which increased the Ventas Fund's assets under management to $2.1 billion.
We define Adjusted EBITDA as consolidated earnings before interest, taxes, depreciation and amortization (including non-cash stock-based compensation expense, asset impairment and valuation allowances), excluding gains or losses on extinguishment of debt, our partners' share of EBITDA of consolidated entities, merger-related expenses and deal costs, expenses related to the re-audit and re-review in 2014 of our historical financial statements, net gains or losses on real estate activity, gains or losses on remeasurement of equity interest upon acquisition, changes in the fair value of financial instruments, unrealized foreign currency gains or losses, net expenses or recoveries related to natural disasters and non-cash charges related to leases, and including Ventas' share of EBITDA from unconsolidated entities and adjustments for other immaterial or identified items.
Loss from Unconsolidated Entities The $10.6 million decrease in the loss from unconsolidated entities is primarily due to our share of a non-cash tax expense in the first quarter of 2020 from one of our unconsolidated operating entities.
However, from time to time,...Read more
We aim to enhance shareholder...Read more
43 Cash Flows The following...Read more
This is partially offset by...Read more
39 Adjusted EBITDA We consider...Read more
Described below are the non-GAAP...Read more
Interest Expense The $5.9 million...Read more
Liquidity and Capital Resources During...Read more
Our chief operating decision makers...Read more
However, since real estate values...Read more
As of March 31, 2021,...Read more
The office segment NOI decrease...Read more
In addition, from time to...Read more
In the first quarter of...Read more
See "Non-GAAP Financial Measures" included...Read more
The following table sets forth...Read more
As of March 31, 2021,...Read more
However, an inability to access...Read more
Allowance on Loans Receivable and...Read more
You should not consider these...Read more
However, from time to time,...Read more
Our weighted average effective interest...Read more
We expect that these liquidity...Read more
Funds From Operations and Normalized...Read more
As of March 31, 2021,...Read more
In order to continue to...Read more
Other The $15.2 million change...Read more
In addition, we will be...Read more
Guarantor and Issuer Financial Information...Read more
First Quarter 2021 Highlights Investments...Read more
Through our Lillibridge Healthcare Services,...Read more
As of March 31, 2021,...Read more
The secured revolving construction credit...Read more
However, if our judgment or...Read more
Under certain circumstances, contractual and...Read more
Our ability to access capital...Read more
We expect that these liquidity...Read more
The non-GAAP financial measures we...Read more
The decrease in normalized FFO...Read more
Nareit defines FFO as net...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Ventas Inc provided additional information to their SEC Filing as exhibits
Ticker: VTR
CIK: 740260
Form Type: 10-Q Quarterly Report
Accession Number: 0000740260-21-000101
Submitted to the SEC: Fri May 07 2021 5:03:17 PM EST
Accepted by the SEC: Fri May 07 2021
Period: Wednesday, March 31, 2021
Industry: Real Estate Investment Trusts